3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Prostatic Neoplasms
3
Herpes Zoster
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Uterine Cervical Dysplasia
2
Papillomavirus Infections
2
Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Influenza, Human
2
Glioblastoma
2
Whooping Cough
1
Waldenstrom Macroglobulinemia
1
Tetanus
1
Spondylitis, Ankylosing
1
Psoriasis
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Glandular and Epithelial
1
Multiple Myeloma
1
Meningitis
1
Medulloblastoma
1
Hematologic Neoplasms
1
Glioma
1
Diphtheria
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Crohn Disease
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Interventions
Cyclophosphamide
34
fludarabine
25
fludarabine phosphate
24
Tacrolimus
24
Mycophenolic Acid
23
Whole-Body Irradiation
22
Busulfan
15
Methotrexate
12
Melphalan
12
Granulocyte Colony-Stimulating Factor
12
Antilymphocyte Serum
12
thymoglobulin
11
Cyclosporine
11
Stem Cell Transplantation
10
Filgrastim
10
Rituximab
9
Thiotepa
7
Peripheral Blood Stem Cell Transplantation
7
Nivolumab
7
Dexamethasone
7
trametinib
6
Radiotherapy
6
Mesna
6
Cytarabine
6
Prednisone
5
Calcium Dobesilate
5
Bortezomib
5
Azacitidine
5
Alemtuzumab
5
Voriconazole
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hematologic Neoplasms
×
Vaccines
×
Clear all
NCT01254630
2019-09-30
V212-011
Merck Sharp & Dohme LLC
Phase 3
Completed
5,305 enrolled
20 charts